1. Durvalumab-associated vasculitis presenting as 'the blue toe syndrome'.
- Author
-
Gupta S, Xu D, Hadfield J, and Prentice D
- Subjects
- Aged, 80 and over, Antibodies, Monoclonal therapeutic use, Antineoplastic Agents, Immunological therapeutic use, Blue Toe Syndrome drug therapy, Blue Toe Syndrome pathology, Carcinoma, Non-Small-Cell Lung classification, Female, Glucocorticoids therapeutic use, Humans, Lung Neoplasms pathology, Prednisolone therapeutic use, Treatment Outcome, Vasculitis drug therapy, Antibodies, Monoclonal adverse effects, Antineoplastic Agents, Immunological adverse effects, Blue Toe Syndrome chemically induced, Carcinoma, Non-Small-Cell Lung drug therapy, Vasculitis chemically induced
- Abstract
Durvalumab is a selective, high-affinity human immunoglobulin monoclonal antibody in a class called check point inhibitors, that blocks PD-L1 on tumour cells. Despite clinical success in increasing progression-free survival rates in patients with stage III non-small-cell lung cancer, durvalumab has been associated with immune-related side effects such as pneumonitis and colitis. We present a case of an 84-year-old woman with acral vasculitis presenting as blue toe syndrome, associated with prolonged use of durvalumab. After 1 year of fortnightly durvalumab therapy postchemoradiation therapy, the patient came in with a left blue big toe, and later developed bilateral livedo racemosa. The diagnosis of durvalumab-associated vasculitis was made and treatment with prednisolone was started with clinical improvement., Competing Interests: Competing interests: None declared., (© BMJ Publishing Group Limited 2020. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2020
- Full Text
- View/download PDF